Wu Jie is the Head of APAC at MPM BioImpact, where she focuses exclusively on early-stage investment and company creation opportunities in the region.

Prior to joining MPM BioImpact, Wu Jie spent 16 years with Temasek and invested in healthcare companies across different geographies and subsectors, including Juno Therapeutics, Guardant Health and JW Therapeutics. She most recently served as Director of Life Sciences Investment at Temasek International in Singapore, where she led a team to develop new markets across APAC regions. Before that, she served as Director of Temasek’s China Investment Team, devising and implementing the firm’s China healthcare strategy and building an extensive network of leading scientists and innovators across Asia.

Wu Jie received a M.S. degree in biotechnology from Johns Hopkins University, as well as both a M.S. and B.S. degree in engineering from Princeton University. In her free time, she enjoys badminton and multi-day hikes.